Liftoff’s 2024 App Marketer Survey Reveals Marketers are Chasing More Aggressive KPI Targets in a More Dynamic Economic Climate
Data from over 500 app marketing professionals finds 58% of marketers are chasing more aggressive KPI targets, while 80% expect their ad spend to stay the same or increase in 2024 SAN FRANCISCO, Jan. 8, 2024 /PRNewswire/ — Liftoff, the leading growth acceleration platform for the mobile indust
Hesai Announces Two Revolutionary New ADAS Lidar Products and Completion of Its State-of-the-Art R&D Center for Manufacturing
Introduce the world’s most advanced, highest performance ADAS lidar, Hesai AT512, boasting the industry’s longest range and transformative highest ever resolution.Display Hesai’s new ultra-thin 25 mm ET25 lidar with super long range and ultra-fine resolution, and designed to be mou
ABF (Ajinomoto Build-up Film) Market Size was Valued at USD 537.5 Million in 2024 and is Anticipated to Grow USD 845.4 Million by 2030 at a CAGR of 7.8% | Valuates Reports
BANGALORE, India, Jan. 8, 2024 /PRNewswire/ — ABF Market is Segmented by Type (Df :Above 0.01, Df :Below 0.01), by Application (Servers & Data Center, PC, Communication Base Station, HPC/AI Chips). The global ABF (Ajinomoto Build-up Film) Market was valued at USD 482.5 Million in 2023
Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
HOLON, Israel, Jan. 8, 2024 /PRNewswire/ — Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that Compugen is entitled to receive a $10 million milestone payment from AstraZeneca (LSE/STO/Na
U.S. District Court Issues Decision on REGENXBIO and University of Pennsylvania NAV® Technology Patent Infringement Lawsuit
ROCKVILLE, Md., Jan. 8, 2024 /PRNewswire/ — REGENXBIO Inc. (Nasdaq: RGNX) today announced the U.S. District Court for the District of Delaware granted Sarepta Therapeutics, Inc. (Sarepta) summary judgment on invalidity in a patent infringement suit arising from Sarepta’s manufacture and
Evergreen Home Loans Promotes Siara Jay to the Position of Branch Manager for the Enumclaw Branch, Following the Retirement of Tara Rose
BELLEVUE, Wash., Jan. 8, 2024 /PRNewswire/ — Evergreen Home Loans, a full-service direct home loan lender offering origination, funding, and servicing throughout the Western U.S., is pleased to announce the retirement of Tara Rose, the dedicated Evergreen Branch Manager with over 30 years of e
Haystack Oncology and Alliance Foundation Trials collaborate to use Haystack MRD™ technology in phase II clinical trial for unresectable stage III NSCLC
BALTIMORE, Jan. 8, 2024 /PRNewswire/ — Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, has entered into a collaboration with Alliance Foundation Trials, LLC (AFT) for research use of Haystack Oncology’s personalized MRD technology (Haystack MRD™) to analyze therapeutic resp
MediDrive®, a CTG Partner Company, announces formal entry into the Non-Emergency Medical Transportation Market
The new company’s mission is to address the critical issue of transportation as a social determinant capable of driving materially improved health outcomes by providing compassionate access to care. BROOKLYN, N.Y., Jan. 8, 2024 /PRNewswire/ — For over forty-five years, the Corporate Tran
WPG Americas Inc. Rick Hylka Receives Top Distribution FAE Award from Micron Technology Inc.
SAN JOSE, Calif., Jan. 8, 2024 /PRNewswire/ — WPG Americas, Inc. (WPGA), a subsidiary of WPG Holdings, a global leading, and largest electronics distributor in Asia*, and now one of the fastest growing in the United States, announced today that Rick Hylka, Innovation Tech Center (ITC) Applicat
CollPlant’s CEO to Present at the Octane Aesthetic Tech Forum Conference, in Newport Beach, California
REHOVOT, Israel, Jan. 8, 2024 /PRNewswire/ — CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced that